Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.53 |
| ▸ | ADH1C | P00326 | 1/20 | 0.53 |
| ▸ | ADH1A | P07327 | 1/20 | 0.53 |
| ▸ | ADH7 | P40394 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568013 | 0.81 | SMN1; SMN2 (0.50) | ADH1BADH1CADH1AADH7CA1 | |
| SCHEMBL8763196 | 0.81 | ADH1B (0.76) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL2585591 | 0.81 | CA2 (0.61) | ADH1BADH1CADH1AADH7CA1 | |
| SCHEMBL3930628 | 0.79 | EPHX2 (0.44) | EPHX2NR1H4ENPP2CA1CA2 | |
| SCHEMBL568564 | 0.79 | ADH1B (0.52) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL14508573 | 0.78 | EPHX2 (0.46) | EPHX2NR1H4ENPP2CA1CA2 | |
| SCHEMBL568631 | 0.78 | KDM4E (0.61) | ADH1BADH1CADH1AADH7EPHX2 | |
| SCHEMBL1251842 | 0.78 | EPHX2 (0.49) | EPHX2NR1H4ENPP2CA1CA2 | |
| SCHEMBL5018988 | 0.78 | LMNA (0.56) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL21165326 | 0.77 | CA2 (0.66) | CA1CA2PTGS2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919874-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2021-02-16 | — | — | US | disclosed |
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2019-12-19 | — | — | US | disclosed |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2019-08-06 | — | — | US | disclosed |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2018-08-09 | — | — | US | disclosed |
| EP-3351541-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9938255-B2 | Metalloenzyme inhibitor compounds | VPS-3, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2788343-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (NC) INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2016-07-28 | — | — | US | disclosed |
| US-9309273-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-7879873-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | SHIONOGI & CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2128134-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | Shionogi&Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2042502-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1544199-B1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2008-07-03 | — | — | US | disclosed |
| US-7211572-B2 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1544199-A1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | ADH1B 1080/4885ADH1C 1892/4885ADH1A 2016/4885 |
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GAA, GPX1 | ADH1B 197/4885ADH1C 217/4885ADH1A 278/4885 |
| US-10919874-B2 | Metalloenzyme inhibitor compounds | MMEL1, GAA, GPX1 | ADH1B 197/4885ADH1C 217/4885ADH1A 278/4885 |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | MMP13, MMP3, MMP26 | ADH1B 2296/4885ADH1C 1803/4885ADH1A 2146/4885 |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | ADH1B 1080/4885ADH1C 1892/4885ADH1A 2016/4885 |
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | DNTT, PNP, NNMT | ADH1B 727/4885ADH1C 1762/4885ADH1A 1975/4885 |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | ADH1B 181/4885ADH1C 220/4885ADH1A 283/4885 |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ADH1B 181/4885ADH1C 220/4885ADH1A 283/4885 |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ADH1B 181/4885ADH1C 220/4885ADH1A 283/4885 |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ADH1B 181/4885ADH1C 220/4885ADH1A 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.